SAM
PCRX icon

Sandell Asset Management’s Pacira BioSciences PCRX Stock Holding History

Sandell Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-180,000
Closed -$6.76M – 39
2017
Q3 		$6.76M Buy
+180,000
New +$7.24M 0.77% 31

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return

Sandell Asset Management's PCRX Position: Q1 2020 in Review

Sandell Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 140,000 shares — an estimated $6.34M sold.

Sandell Asset Management first reported a position in PCRX in Q2 2017 and held it in 11 quarters. The position peaked at $17.2M in Q4 2017. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

  • Sandell Asset Management reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
  • Sandell Asset Management sold 140,000 Pacira BioSciences shares in Q1 2020, an estimated $6.34M.
  • Sandell Asset Management first reported a position in Pacira BioSciences in Q2 2017 and held it in 11 quarters.
  • Sandell Asset Management's Pacira BioSciences position peaked at $17.2M in Q4 2017.
  • 226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Sandell Asset Management's 13F filing for Q1 2020, filed 15 May 2020.